General Mills (GIS)
(Delayed Data from NYSE)
$70.40 USD
+1.20 (1.73%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $70.54 +0.14 (0.20%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth B Momentum C VGM
Price, Consensus and EPS Surprise
GIS 70.40 +1.20(1.73%)
Will GIS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GIS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GIS
General Mills (GIS) Hurt by Volatile Consumer Trends, Cost Woes
Should Kraft Heinz (KHC) be in Your Portfolio Before Q2 Earnings?
GIS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is General Mills (GIS) Up 3.3% Since Last Earnings Report?
Kraft Heinz (KHC) Trading Near 52-Week Low: Buy, Hold or Sell?
3 Top Dividend Stocks to Maximize Your Retirement Income
Other News for GIS
Kellanova unlikely to see other bidders after agreeing to Mars deal - CNBC
Food spotlight: Blockbuster M&A as Mars takes Kellanova private, pantry inflation up 1%
Cheez-It and Skittles! Kellanova soars as Mars confirms merger
Gilead Sciences: A Strong Buy on Solid Financials and Promising R&D Pipeline
Cautious Optimism for Gilead Sciences Awaiting Significant Clinical Wins